Ani Pharmaceuticals (ANIP) Other financing activities (2011 - 2026)

Ani Pharmaceuticals has disclosed Other financing activities across 16 years of filings, most recently posting $308000.0 for Q2 2026.

• In Q2 2026, Other financing activities fell 75.2% year-over-year to $308000.0; the TTM figure through Jun 2026 stood at $12.3 million (up 85.03% YoY), while the FY2025 annual figure was $13.6 million, up 109.68% from the prior year.
• Other financing activities came in at $308000.0 for Q2 2026 at Ani Pharmaceuticals, down from $2.2 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $9.8 million in Q3 2025 to a low of $3000.0 in Q1 2022.
• Average Other financing activities over 5 years is $1.8 million, with a median of $1.2 million recorded in 2024.
• Year-over-year, Other financing activities jumped 5133.33% in 2023 and plunged 97.76% in 2025.
• Over 5 years, Other financing activities stood at $768000.0 in 2022, then surged by 156.38% to $2.0 million in 2023, then fell by 13.66% to $1.7 million in 2024, then sank by 97.76% to $38000.0 in 2025, then jumped by 710.53% to $308000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $308000.0 in Q2 2026, $2.2 million in Q1 2026, and $38000.0 in Q4 2025.